William Blair
http://www.williamblair.comWilliam Blair & Company, L.L.C. is a Chicago-based investment firm offering investment banking, asset management, equity research, institutional and private brokerage, and private capital to individual, institutional, and issuing clients. Since 1935, it has been committed to helping clients achieve their financial objectives.
View Older Stories View More Recent Stories
-
Viking Therapeutics to Present at William Blair Biotech Focus Conference 2022
-
9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022
-
POINT Biopharma to Participate in Upcoming Investor Conferences
-
ReCode Therapeutics to Participate in Upcoming July Investor Conferences
-
Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022
-
Caraway Therapeutics to Participate in William Blair Biotech Focus Conference
-
Entrada Therapeutics to Present at William Blair Biotech Focus Conference
-
Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022
-
Entrada Therapeutics to Present at William Blair Biotech Focus Conference
-
Autolus Therapeutics to Participate in William Blair’s Biotech Focus Conference 2022, New York, July 12 – 13, 2022
-
Autolus Therapeutics to Participate in William Blair’s Biotech Focus Conference 2022, New York, July 12 – 13, 2022
-
Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022
-
Krystal Biotech to Present at William Blair Biotech Focus Conference 2022
-
Taysha Gene Therapies to Participate in Upcoming William Blair Biotech Focus Conference 2022
-
Immuneering Announces Participation in William Blair Biotech Focus Conference 2022
-
Immuneering Announces Participation in William Blair Biotech Focus Conference 2022
-
Chinook Therapeutics to Present at the William Blair Biotech Focus Conference 2022
-
Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference
-
Cullinan Oncology to Participate in William Blair Biotech Focus Conference
-
Cullinan Oncology to Participate in William Blair Biotech Focus Conference
-
William Blair Bolsters Investment Banking Group With Senior Hires in London
-
Cardiff Oncology to Present at the William Blair Biotech Focus Conference 2022
-
BELLUS Health to Participate in the William Blair Biotech Focus Conference
-
Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022
-
Crisis-hit Ghana changes its mind and turns to IMF for help
-
FibroGen to Participate at William Blair Biotech Focus Conference 2022
-
Form D/A William Blair Internatio
-
Shotspotter (SSTI) Shares Have 'Greater Than 60% Upside' - William Blair
-
Knox Lane Announces Strategic Investment in Elevation Labs
-
Palantir's New Contract with US Army Not Enough for Stock to Turn Higher - Analyst
-
Agenus to Participate at William Blair’s Biotech Focus Conference
-
Agenus to Participate at William Blair’s Biotech Focus Conference
-
Albireo to Present at the William Blair Biotech Focus Conference 2022
-
Markets in H1: The almost perfect storm
-
Clearlake Capital To Sell Brightly Software To Siemens for $1.575B Upfront Plus Earn-Out
-
CLEARLAKE CAPITAL TO SELL BRIGHTLY SOFTWARE TO SIEMENS
-
GE CEO Culp expands role to head aviation unit
-
William Blair Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
-
Audax Private Equity Announces Strategic Growth Investment in BlueCat Networks
-
Audax Private Equity Announces Strategic Growth Investment in BlueCat Networks
-
UPDATE: William Blair Downgrades Acuity Brands (AYI) to Market Perform
-
Xenon's (XENE) XEN1101 Has Best in Class Potential, Company is Trading at Attractive Value - William Blair Bullish on Stock
-
Emerging Fintech Market Leader Prime Trust Raises over $100M in Series B Funding to Expand into New Offerings
-
Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares
-
CarMax (KMX) Estimates Cut on Challenging Industry Backdrop - William Blair
-
William Blair Expands Equity Capital Markets Group, Adding Managing Director in New York
-
Arcellx (ACLX) Prices 7M Share Offering at $16/sh
-
Arcellx Announces Upsizing and Pricing of Follow-On Public Offering
-
Form D WILLIAM BLAIR MB INVESTM
-
Bridging the Opportunity Gap: Connecting Black and Latinx Students to Careers in Finance

